Targeting epidermal growth factor receptor in lung cancer.

被引：42

作者：

Baselga J. ^{[1
]}

Albanell J. ^{[1
]}

机构：

[1] Medical Oncology Service, Hospital General Universitari Vall d'Hebron, Paseo Vall d'Hebron 119-129, Barcelona

来源：

Current Oncology Reports | 2002年 / 4卷 / 4期

关键词：

Epidermal Growth Factor Receptor; Epidermal Growth Factor Receptor Expression; Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor; Iressa; Growth Factor Receptor Tyrosine Kinase;

D O I：

10.1007/s11912-002-0007-1

中图分类号：

学科分类号：

摘要：

Among the most promising agents in clinical development to treat non-small-cell lung cancer (NSCLC) are the epidermal growth factor receptor (EGFR) targeting agents. A series of recent studies have demonstrated the activity of anti-EGFR targeted therapies for NSCLC. In advanced NSCLC that is refractory to chemotherapy, antitumor responses have been reported with EGFR tyrosine kinase inhibitors (ZD1839 and OSI-774). The role of ZD1839 and OSI-774 as possible additions to standard chemotherapy in the first-line setting has also been evaluated, and the studies conducted to date should respond to the question of whether these compounds could provide a survival benefit. Other areas of research involve looking at the role of EGFR tyrosine kinase inhibitors in the neoadjuvant treatment of stage III NSCLC and the planning of chemoprevention studies. These exciting results and plans are further complemented by an emerging number of compounds in clinical development, including both monoclonal antibodies (ie, IMC-C225) and other tyrosine kinase inhibitors, directed at the EGFR.

引用

页码：317 / 324

页数：7

共 118 条

[31] Codony-Servat J(2000)Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: final results from a phase I study [abstract] Proc ASCO 19 3-3
[32] Rojo F(2001)Pharmacodynamic studies with the EGFR tyrosine kinase inhibitor ZD1839 Semin Oncol 28 56-66
[33] Bonner JA(2002)Pharmacodynamic studies of the EGF receptor inhibitor ZD1839 (’Iressa’) in skin from cancer patients: histopathological and molecular consequences of receptor inhibition J Clin Oncol 20 110-124
[34] Ezequiel MP(2001)ZD1839 (‘Iressa’), an orally-active, selective, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is well tolerated in combination with gemcitabine and cisplatin, in patients with advanced solid tumours: preliminary tolerability, efficacy and pharmacokinetic results [abstract] Eur J Cancer 37 S30-S31
[35] Robert F(2001)A pilot trial demonstrates the safety of ZD1839 (‘Iressa’), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC) [abstract] Proc ASCO 20 326-326
[36] Rubin MS(1999)Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice J Pharmacol Exp Ther 291 739-748
[37] Shin DM(1999)Phase I dose escalation study of epidermal growth factor tyrosine kinase inhibitor CP-358,774 in patients with advanced solid tumors [abstract] Proc ASCO 18 1499-1499
[38] Pasmantier M(2001)Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies J Clin Oncol 19 3267-3279
[39] Hong WK(2001)Dose-schedule-finding, pharmacokinetic (PK), biologic, and functional imaging studies of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor [abstract] Proc ASCO 20 5A-5A
[40] Arquette M(2001)Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck [abstract] Proc ASCO 20 2-2

← 1 2 3 4 5 6 7 8 9 10 →